Business Wire

Dotmatics Launches New Release of Vortex

Share

Dotmatics, a leading provider of scientific informatics solutions and services, today announced a new release of Vortex with new bioinformatics features that are tailored to support biologics discovery. With this release, and in a single application, biologists and other scientists performing biologics research, can manage, analyze and visualize their data without having to rely on the skills of highly specialized bioinformaticians.

"Bioinformaticians can be scarce and expensive assets in today's scientific organizations, yet not all biologics research requires their expertise," said Andrew LeBeau, PhD, Dotmatics senior manager of biologics marketing. "This enhanced version of Vortex gives biologists and other researchers ready access to commercial grade, scientifically aware informatics tools specifically designed to support the scientific data types involved in biologics discovery. Ultimately, this makes research easier for biologists and allows bioinformaticians to spend their time on highly specialized analyses and the development of new algorithms valuable to scientific organizations."

"Vortex for Bioinformatics provides a rich set of tools for biologics research within an integrated environment, giving researchers the ability to handle high data volumes, potentially aggregated from multiple sources, along with the necessary analytical and visualization capabilities that allow them to advance their scientific experiments," said Tom Oldfield, PhD, Dotmatics principal software architect. "In addition, the latest version of Vortex offers new support for antibody discovery programs that focus on creating novel monoclonal antibodies and other antibody-derived or related molecules to solve some of the biggest challenges in healthcare, agbio and other industries."

Available March, 2018, Vortex for Bioinformatics is a set of analytical tools and visualization capabilities for biological information discovery that can be used for pure biology research but also integrates with the existing cheminformatics features of Vortex. The tools include analysis and visualization methods for many different bio-science data types, with a particular focus on sequence data, and are specifically designed to work with very large data volumes, such as millions of DNA, RNA or peptide/protein sequences. Vortex for Bioinformatics complements the entire Dotmatics Suite, including Bioregister, Studies Notebook and Studies.

Some of the many new Vortex features include:

  • Manual sequence editing capabilities to design and implement mutations, and to create insertions and deletions, enhancing the use of Vortex for designing variant antibodies and other sequence-based entities
  • Significant extension of sequence annotation capabilities, allowing multiple and overlapping annotation to be added manually and algorithmically
  • Sequence search capabilities that allow users to quickly navigate sequences to find occurrences of important residues and sequence motifs
  • Sequence numbering enhancements to support antibody discovery
  • Complementary Determining Region (CDR) alignment, annotation and coloring capabilities that allow easier analysis of relative antibody function

Customers with an existing license to Vortex may access the latest version at no additional cost. For more information, please register to attend the 8:00 am Pacific/5:00 pm CET, March 22 What’s New in Vortex for Bioinformatics webinar.

About Dotmatics:

Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organizations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualization. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information visit dotmatics.com.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Dotmatics
Marla Kertzman, 209-852-9027
pr@dotmatics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release

Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release

IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release

HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye